Search

Your search keyword '"Loghavi, Sanam"' showing total 1,284 results
Start Over Author "Loghavi, Sanam"
1,284 results on '"Loghavi, Sanam"'

52. Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

Author

Lachowiez, Curtis A, Reville, Patrick K, Kantarjian, Hagop, Jabbour, Elias, Borthakur, Gautam, Daver, Naval, Loghavi, Sanam, Furudate, Ken, Xiao, Lianchun, Pierce, Sherry, Short, Nicholas J, Maiti, Abhishek, Yilmaz, Musa, Sasaki, Koji, Takahashi, Koichi, Konopleva, Marina, Pemmaraju, Naveen, Popat, Uday, Shpall, Elizabeth, Garcia-Manero, Guillermo, Ravandi, Farhad, DiNardo, Courtney D, and Kadia, Tapan M

Published
2022
Full Text
View/download PDF

56. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.

Author

Senapati, Jayastu, Kantarjian, Hagop M., Bazinet, Alexandre, Reville, Patrick, Short, Nicholas J., Daver, Naval, Borthakur, Gautam, Bataller, Alex, Jabbour, Elias, DiNardo, Courtney, Haddad, Fadi, Sasaki, Koji, Popat, Uday, Oran, Betul, Alousi, Amin M., Loghavi, Sanam, Shpall, Elizabeth, Garcia‐Manero, Guillermo, Ravandi, Farhad, and Kadia, Tapan M.

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, OLDER patients, VENETOCLAX, SURVIVAL rate, HEMATOPOIETIC stem cell transplantation
Abstract

Background: Allogeneic stem cell transplantation (SCT) remains the best consolidative modality in most patients with acute myeloid leukemia (AML). Along with factors directly pertaining to SCT, pretransplantation disease control, performance status, and prior treatment‐related complications are important factors that affect posttransplantation survival outcomes. Methods: The authors compared the survival outcomes of patients ≥60 years of age treated on the phase 2 clinical trial of venetoclax (Ven) added to cladribine (CLAD) and low dose cytarabine (LDAC) alternating with azacitidine (CLAD/LDAC/Ven arm) (NCT03586609) who underwent allogeneic SCT in first remission to a retrospective cohort of patients ≥60 years of age who underwent SCT after intensive chemotherapy. Intensive chemotherapy was defined as the use of cytarabine >1 g/m2 and anthracyclines during induction/consolidation. Results: Thirty‐five patients at median age of 68 years in the CLAD/LDAC/Ven arm were compared to 42 patients at a median age of 62 years in the intensive therapy arm. The 2‐year relapse‐free survival was superior with CLAD/LDAC/Ven versus intensive chemotherapy (88% vs. 65%; p =.03) whereas the 2‐year overall survival (OS) was comparable (84% vs. 70%; p =.14). On a competing event analysis, the 2‐year cumulative incidence of relapse (CIR) was significantly lower with CLAD/LDAC/Ven versus intensive chemotherapy (2.9% vs. 17.2%, Gray's p =.049) whereas nonrelapse mortality was comparable (16.2% vs. 17.1%; p =.486). Conclusion: In conclusion, treatment with CLAD/LDAC/Ven was associated with favorable outcomes in older patients who underwent subsequent allogeneic SCT. The OS was comparable to that with intensive chemotherapy followed by allogeneic SCT, but the CIR rate was significantly lower. Older patients (≥60 years of age) with acute myeloid leukemia who underwent allogeneic stem cell transplantation after low‐intensity therapy on the phase 2 trial of venetoclax added to cladribine and low dose cytarabine alternating with azacitidine had promising survival outcomes that were comparable to a retrospective cohort of patients who underwent allogeneic stem cell transplantation after intensive chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

57. Long-term results of the sequential combination of cladribine and rituximab in Hairy cell leukemia.

Author

Marvin-Peek, Jennifer, Jen, Wei-Ying, Kantarjian, Hagop M., McCue, David, Haddad, Fadi G., Wierda, William, Ferrajoli, Alessandra, Burger, Jan, Abusab, Tareq, Jorgensen, Jeffrey, Wang, Sa A., Patel, Keyur, Loghavi, Sanam, O'Brien, Susan, and Ravandi, Farhad

Subjects
HAIRY cell leukemia, DISEASE relapse, OVERALL survival, PATIENTS' attitudes, RITUXIMAB
Abstract

We report on the long-term efficacy and safety of a phase 2 trial of sequential cladribine and rituximab in hairy cell leukemia (HCL). One-hundred and thirty-nine patients were enrolled: 111 in the frontline setting, 18 in first relapse, and 10 with variant HCL (HCLv). A complete response (CR) was achieved in 133 of 137 evaluable participants (97%) with measurable residual disease (MRD) negativity in 102 (77%). MRD status was not associated with significant differences in event-free survival (EFS) or overall survival (OS). With a median follow-up of 7.8 years (range: 0.40–18.8), eight patients have experienced disease relapse (5.8%), 4/111 with newly diagnosed HCL (3·6%) and 4/10 with HCLv (40%) (p = 0.002). The 10-year EFS and OS rates were 86.7% and 91.1%, respectively. Grade 3 adverse events were observed in 28 participants (20·1%), mostly due to infections. Treatment of HCL with sequential cladribine followed by rituximab is associated with excellent efficacy and safety results both in the frontline and relapsed settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

58. Future of Education or Present Reality?: MD Anderson Cancer Center Hematopathology Virtual Educational Platform During the Coronavirus Disease 2019 (COVID-19) Pandemic

Author

Lyapichev, Kirill A., Loghavi, Sanam, Hussein, Siba El, Maghrabi, Haneen Al-, Xu, Jie, Konoplev, Sergej, Medeiros, L. jeffrey, and Khoury, Joseph D.

Subjects
Epidemics -- Educational aspects -- United States, Clinical pathology -- Educational aspects, Hematology -- Educational aspects, Medical education -- Methods -- Forecasts and trends, Online education -- Methods -- Forecasts and trends, Market trend/market analysis, Health
Abstract

Context.--The main focus of education in most pathology residency and subspecialty pathology fellowships is the light microscopic examination of pathology specimens. Classes with multiheaded scopes are the most popular among pathology trainees. Until recently, it was difficult to imagine that this educational approach could change. In the beginning of March 2020, our country faced a serious challenge, which all of us now know as the coronavirus disease 2019 (COVID-19) pandemic. The rules of social distancing and work from home were applied. These types of restrictions were implemented in almost all parts of our life, including work and pathology education. Objective.--To share our experience in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center during the COVID-19 pandemic. We describe our experience in modifying our approaches to education. We show how we overcame many obstacles to learning by building one of the largest virtual hematopathology educational platforms via Cisco WebEx and using social media, in particular Twitter. These tools facilitated the learning of hematopathology by medical students, pathology trainees, and practicing pathologists from all over the world. Data Sources.--During the first 3 months of the pandemic (April, May, and June, 2020), we evaluated the visitor attendance to the MD Anderson Cancer Center Hematopathology Virtual Educational Platform using data collected by the Cisco WebEx Web site. To determine the impact that the platform had on medical education for the hematopathology community on Twitter, the analytic metrics obtained from Symplur LLC (www.symplur.com, April 27, 2020) were used via its Symplur Signals program. Conclusions.--Our experience using the MD Anderson Hematopathology Virtual Platform showed that there is substantial global interest and desire for virtual hematopathology education, especially during the COVID-19 pandemic. (Arch Pathol Lab Med. 2021;145:1350-1354; doi: 10.5858/arpa.2021-0195-SA), The recent coronavirus disease 2019 (COVID-19) pandemic challenged every part of our lives. Social distancing practices to prevent the spread of viral infection made traditional pathology sign-out and education using [...]

Published
2021
Full Text
View/download PDF

60. Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression

Author

Jen, Wei‐Ying, primary, Sasaki, Koji, additional, Loghavi, Sanam, additional, Wang, Sa A., additional, Qiao, Wei, additional, Borthakur, Gautam, additional, Ravandi, Farhad, additional, Kadia, Tapan M., additional, Issa, Ghayas C., additional, Short, Nicholas J., additional, Yilmaz, Musa, additional, Daver, Naval G., additional, and DiNardo, Courtney D., additional

Published
2024
Full Text
View/download PDF

61. Myeloid neoplasm with <10% blasts and t(3;5)(q25.1;q34)/NPM::MLF1: A classification dilemma

Author

Sameeta, Fnu, primary, Fang, Hong, additional, Wang, Wei, additional, Tang, Zhenya, additional, Wang, Sa A., additional, Toruner, Gokce A., additional, Parisi, Xenia, additional, Khoury, Joseph D., additional, Issa, Ghayas, additional, Garcia‐Manero, Guillermo, additional, Medeiros, L. Jeffrey, additional, Tang, Guilin, additional, and Loghavi, Sanam, additional

Published
2024
Full Text
View/download PDF

63. Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups

Author

Bataller, Alex, primary, DiNardo, Courtney D., additional, Bazinet, Alexandre, additional, Daver, Naval G., additional, Maiti, Abhishek, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Sasaki, Koji, additional, Jabbour, Elias J., additional, Issa, Ghayas C., additional, Pemmaraju, Naveen, additional, Yilmaz, Musa, additional, Montalban‐Bravo, Guillermo, additional, Loghavi, Sanam, additional, Garcia‐Manero, Guillermo, additional, Ravandi, Farhad, additional, Kantarjian, Hagop M., additional, and Kadia, Tapan M., additional

Published
2024
Full Text
View/download PDF

66. Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML

Author

Yilmaz, Musa, Kantarjian, Hagop, Short, Nicholas J., Reville, Patrick, Konopleva, Marina, Kadia, Tapan, DiNardo, Courtney, Borthakur, Gautam, Pemmaraju, Naveen, Maiti, Abhishek, Jabbour, Elias, Jain, Nitin, Issa, Ghayas, Takahashi, Koichi, Sasaki, Koji, Ohanian, Maro, Pierce, Sherry, Tang, Guillin, Loghavi, Sanam, Patel, Keyur, Wang, Sa A., Garcia-Manero, Guillermo, Andreeff, Michael, Ravandi, Farhad, and Daver, Naval

Published
2022
Full Text
View/download PDF

67. Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Author

Lachowiez, Curtis A., Loghavi, Sanam, Furudate, Ken, Montalban-Bravo, Guillermo, Maiti, Abhishek, Kadia, Tapan, Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Sasaki, Koji, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas J., Chien, Kelly, Ohanian, Maro, Pierce, Sherry, Patel, Keyur P., Jabbour, Elias, Ravandi, Farhad, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Takahashi, Koichi, Konopleva, Marina Y., and DiNardo, Courtney D.

Published
2021
Full Text
View/download PDF

73. Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1

Author

Quesada, Andrés E., Montalban-Bravo, Guillermo, Luthra, Rajyalakshmi, Patel, Keyur P., Sasaki, Koji, Bueso-Ramos, Carlos E., Khoury, Joseph D., Routbort, Mark.J., Bassett, Roland, Hidalgo-Lopez, Juliana E., Zhao, Chong, Lin, Pei, Loghavi, Sanam, Ok, Chi Y., Kadia, Tapan, DiNardo, Courtney D., Kantarjian, Hagop, Garcia-Manero, Guillermo, and Kanagal-Shamanna, Rashmi

Published
2020
Full Text
View/download PDF

75. A proposal for pathologic processing of breast implant capsules in patients with suspected breast implant anaplastic large cell lymphoma

Author

Lyapichev, Kirill A., Piña-Oviedo, Sergio, Medeiros, L.Jeffrey, Evans, Mark G., Liu, Hui, Miranda, Alonso R., Hunt, Kelly K., Clemens, Mark W., Stewart, John M., Amin, Mitual B., Quesada, Andres E., Chai, Siaw Ming, Di Napoli, Arianna, Yoga, Arthy, Dave, Sanat K., Wistuba, Ignacio I., Wu, Yun, Bueso-Ramos, Carlos E., Schlette, Ellen J., Ferrufino-Schmidt, Maria C., Loghavi, Sanam, Khoury, Joseph D., Young, Ken H., and Miranda, Roberto N.

Published
2020
Full Text
View/download PDF

76. T-Cell–Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features

Author

El Hussein, Siba, primary, Fang, Hong, additional, Jelloul, Fatima Zahra, additional, Wang, Wei, additional, Loghavi, Sanam, additional, Miranda, Roberto N., additional, Friedberg, Jonathan W., additional, Burack, W. Richard, additional, Evans, Andrew G., additional, Xu, Jie, additional, and Medeiros, L. Jeffrey, additional

Published
2023
Full Text
View/download PDF

77. Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents

Author

Montalban‐Bravo, Guillermo, primary, Jabbour, Elias, additional, Borthakur, Gautam, additional, Kadia, Tapan, additional, Ravandi, Farhad, additional, Chien, Kelly, additional, Pemmaraju, Naveen, additional, Hammond, Danielle, additional, Dong, Xiao Qin, additional, Huang, Xuelin, additional, Schneider, Heather, additional, John, Rosmy, additional, Kanagal‐Shamana, Rashmi, additional, Loghavi, Sanam, additional, Kantarjian, Hagop, additional, and Garcia‐Manero, Guillermo, additional

Published
2023
Full Text
View/download PDF

78. 86. Diagnostic challenges of high-grade myeloid malignancies with partial plasmacytoid dendritic cell differentiation

Author

Nahmod, Karen, primary, Miranda, Roberto, additional, Vega, Francisco, additional, Thakral, Beenu, additional, Pemmaraju, Naveen, additional, Loghavi, Sanam, additional, Jelloul, Fatima, additional, Wang, Wei, additional, Wang, Sa, additional, Muzzafar, Tariq, additional, Patel, Keyur, additional, Bueso-Ramos, Carlos, additional, Medeiros, L. Jeffrey, additional, and Kanagal-Shamanna, Rashmi, additional

Published
2023
Full Text
View/download PDF

80. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy

Author

Venugopal, Sangeetha, Takahashi, Koichi, Daver, Naval, Maiti, Abhishek, Borthakur, Gautam, Loghavi, Sanam, Short, Nicholas. J., Ohanian, Maro, Masarova, Lucia, Issa, Ghayas, Wang, Xuemei, Carlos, Bueso-Ramos, Yilmaz, Musa, Kadia, Tapan, Andreeff, Michael, Ravandi, Farhad, Konopleva, Marina, Kantarjian, Hagop M., and DiNardo, Courtney D.

Published
2022
Full Text
View/download PDF

81. Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics

Author

Morita, Kiyomi, Wang, Feng, Jahn, Katharina, Hu, Tianyuan, Tanaka, Tomoyuki, Sasaki, Yuya, Kuipers, Jack, Loghavi, Sanam, Wang, Sa A., Yan, Yuanqing, Furudate, Ken, Matthews, Jairo, Little, Latasha, Gumbs, Curtis, Zhang, Jianhua, Song, Xingzhi, Thompson, Erika, Patel, Keyur P., Bueso-Ramos, Carlos E., DiNardo, Courtney D., Ravandi, Farhad, Jabbour, Elias, Andreeff, Michael, Cortes, Jorge, Bhalla, Kapil, Garcia-Manero, Guillermo, Kantarjian, Hagop, Konopleva, Marina, Nakada, Daisuke, Navin, Nicholas, Beerenwinkel, Niko, Futreal, P. Andrew, and Takahashi, Koichi

Published
2021
Full Text
View/download PDF

82. Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML

Author

Yilmaz, Musa, Alfayez, Mansour, DiNardo, Courtney D., Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Loghavi, Sanam, Kanagal-Shamanna, Rashmi, Patel, Keyur P., Jabbour, Elias J., Garcia‑Manero, Guillermo, Pemmaraju, Naveen, Pierce, Sherry A., Ghayas, Issa, Short, Nicholas J., Montalban-Bravo, Guillermo, Takahashi, Koichi, Assi, Rita, Alotaibi, Ahmad S., Ohanian, Maro, Andreeff, Michael, Cortes, Jorge E., Kantarjian, Hagop M., Ravandi, Farhad, and Daver, Naval G.

Published
2021
Full Text
View/download PDF

90. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Author

Short, Nicholas J, Kantarjian, Hagop M, Loghavi, Sanam, Huang, Xuelin, Qiao, Wei, Borthakur, Gautam, Kadia, Tapan M, Daver, Naval, Ohanian, Maro, Dinardo, Courtney D, Estrov, Zeev, Kanagal-Shamanna, Rashmi, Maiti, Abhishek, Benton, Christopher B, Bose, Prithviraj, Alvarado, Yesid, Jabbour, Elias, Kornblau, Steven M, Pemmaraju, Naveen, Jain, Nitin, Gasior, Yvonne, Richie, Mary Ann, Pierce, Sherry, Cortes, Jorge, Konopleva, Marina, Garcia-Manero, Guillermo, and Ravandi, Farhad

Published
2019
Full Text
View/download PDF

91. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Author

Ganan-Gomez, Irene, Yang, Hui, Ma, Feiyang, Montalban-Bravo, Guillermo, Thongon, Natthakan, Marchica, Valentina, Richard-Carpentier, Guillaume, Chien, Kelly, Manyam, Ganiraju, Wang, Feng, Alfonso, Ana, Chen, Shuaitong, Class, Caleb, Kanagal-Shamanna, Rashmi, Ingram, Justin P., Ogoti, Yamini, Rose, Ashley, Loghavi, Sanam, Lockyer, Pamela, Cambo, Benedetta, Muftuoglu, Muharrem, Schneider, Sarah, Adema, Vera, McLellan, Michael, Garza, John, Marchesini, Matteo, Giuliani, Nicola, Pellegrini, Matteo, Wang, Jing, Walker, Jason, Li, Ziyi, Takahashi, Koichi, Leverson, Joel D., Bueso-Ramos, Carlos, Andreeff, Michael, Clise-Dwyer, Karen, Garcia-Manero, Guillermo, and Colla, Simona

Published
2022
Full Text
View/download PDF

92. Intrauterine Growth Restriction Caused by Underlying Congenital Cytomegalovirus Infection

Author

Pereira, Lenore, Petitt, Matthew, Fong, Alex, Tsuge, Mitsuru, Tabata, Takako, Fang-Hoover, June, Maidji, Ekaterina, Zydek, Martin, Zhou, Yan, Inoue, Naoki, Loghavi, Sanam, Pepkowitz, Samuel, Kauvar, Lawrence M, and Ogunyemi, Dotun

Subjects
Medical Microbiology, Reproductive Medicine, Biomedical and Clinical Sciences, Preterm, Low Birth Weight and Health of the Newborn, Pediatric, Infectious Diseases, Perinatal Period - Conditions Originating in Perinatal Period, Infant Mortality, Conditions Affecting the Embryonic and Fetal Periods, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Aetiology, Infection, Reproductive health and childbirth, Good Health and Well Being, Antibodies, Neutralizing, Antibodies, Viral, Cytomegalovirus Infections, DNA, Viral, Female, Fetal Growth Retardation, Humans, Immunoglobulin G, Infant, Newborn, Infectious Disease Transmission, Vertical, Pilot Projects, Pregnancy, Pregnancy Complications, Infectious, Serologic Tests, congenital, HCMV, IUGR, pregnancy, fetus, placenta, villi, chorion, amnion, blood vessels, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundHuman cytomegalovirus (HCMV) is the major viral etiology of congenital infection and birth defects. Fetal transmission is high (30%-40%) in primary maternal infection, and symptomatic babies have permanent neurological, hearing, and vision defects. Recurrent infection is infrequently transmitted (2%) and largely asymptomatic. Congenital infection is also associated with intrauterine growth restriction (IUGR).MethodsTo investigate possible underlying HCMV infection in cases of idiopathic IUGR, we studied maternal and cord sera and placentas from 19 pregnancies. Anti-HCMV antibodies, hypoxia-related factors, and cmvIL-10 were measured in sera. Placental biopsy specimens were examined for viral DNA, expression of infected cell proteins, and pathology.ResultsAmong 7 IUGR cases, we identified 2 primary and 3 recurrent HCMV infections. Virus replicated in glandular epithelium and lymphatic endothelium in the decidua, cytotrophoblasts, and smooth muscle cells in blood vessels of floating villi and the chorion. Large fibrinoids with avascular villi, edema, and inflammation were significantly increased. Detection of viral proteins in the amniotic epithelium indicated transmission in 2 cases of IUGR with primary infection and 3 asymptomatic recurrent infections.ConclusionsCongenital HCMV infection impairs placental development and functions and should be considered as an underlying cause of IUGR, regardless of virus transmission to the fetus.

Published
2014

93. Phase 1/2 study of CPX‐351 for patients with Int‐2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.

Author

Montalban‐Bravo, Guillermo, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan, Ravandi, Farhad, Chien, Kelly, Pemmaraju, Naveen, Hammond, Danielle, Dong, Xiao Qin, Huang, Xuelin, Schneider, Heather, John, Rosmy, Kanagal‐Shamana, Rashmi, Loghavi, Sanam, Kantarjian, Hagop, and Garcia‐Manero, Guillermo

Subjects
CHRONIC leukemia, MYELODYSPLASTIC syndromes, CARDIOTOXICITY, FEBRILE neutropenia, LUNG infections
Abstract

Summary: Failure after hypomethylating agents (HMAs) is associated with dismal outcomes in higher risk myelodysplastic syndromes (HR‐MDS) or chronic myelomonocytic leukaemia (CMML). We aimed to evaluate the safety and preliminary activity of lower doses of CPX‐351, a liposomal encapsulation of cytarabine and daunorubicin, in a single‐centre, phase 1/2 study for patients with HR‐MDS or CMML after HMA failure. Four doses of CPX‐351 (10, 25, 50 and 75 units/m2) administered on Days 1, 3 and 5 of induction and Days 1 and 3 of consolidation were evaluated. Between June 2019 and June 2023, 25 patients were enrolled (phase 1: n = 15; phase 2: n = 10) including 19 (76%) with HR‐MDS and 6 (24%) with CMML. Most common grade 3–4 non‐haematological treatment‐emergent adverse events were febrile neutropenia (n = 12, 48%) and lung infection (n = 5, 20%). Three patients (age >75) experienced cardiac toxicity at the 75 units/m2 dose. Further enrolment continued at 50 units/m2. Four‐ and 8‐week mortality were 0% and 8% respectively. The overall response rate was 56% with median relapse‐free and overall survivals of 9.2 (95% CI 3.2–15.1 months) and 8.7 months (95% CI 1.8–15.6 months) respectively. These data suggest that lower doses of CPX‐351 are safe. Further studies are needed to evaluate its activity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

95. BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or Menin inhibitor

Author

Fiskus, Warren C, primary, Piel, Jessica, additional, Collins, Mike, additional, Hentemann, Murphy, additional, Cuglievan, Branko, additional, Mill, Christopher P, additional, Birdwell, Christine E, additional, Das, Kaberi, additional, Davis, John A, additional, Hou, Hanxi, additional, Jain, Antrix C, additional, Malovannaya, Anna, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Sasaki, Koji, additional, Takahashi, Koichi, additional, Hammond, Danielle, additional, Reville, Patrick K, additional, Wang, Jian, additional, Loghavi, Sanam, additional, Sen, Rwik, additional, Ruan, Xinjia, additional, Su, Xiaoping, additional, Flores, Lauren B, additional, DiNardo, Courtney D, additional, and Bhalla, Kapil N, additional

Published
2023
Full Text
View/download PDF

96. IL-1β–mediated inflammatory signaling drives ineffective erythropoiesis in early-stage myelodysplastic syndromes

Author

Adema, Vera, primary, Ganan-Gomez, Irene, additional, Ma, Feiyang, additional, Rodriguez-Sevilla, Juan Jose, additional, Chien, Kelly, additional, Yang, Hui, additional, Thongon, Natthakan, additional, Kanagal-Shamanna, Rashmi, additional, Loghavi, Sanam, additional, Montalban-Bravo, Guillermo, additional, Hammond, Danielle, additional, Gu, Yiqian, additional, Tan, Roselyn, additional, Tan, Lin, additional, Lorenzi, Philip, additional, Al-Atrash, Gheath, additional, Clise-Dwyer, Karen, additional, Bejar, Rafael, additional, Pellegrini, Matteo, additional, Garcia-Manero, Guillermo, additional, and Colla, Simona, additional

Published
2023
Full Text
View/download PDF

97. Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic Syndromes

Author

Rodriguez Sevilla, Juan Jose, primary, Ganan-Gomez, Irene, additional, Ma, Feyiang, additional, Chien, Kelly, additional, Montalban-Bravo, Guillermo, additional, Kanagal-Shamanna, Rashmi, additional, Loghavi, Sanam, additional, Adema, Vera, additional, Bazinet, Alexandre, additional, Garcia-Manero, Guillermo, additional, and Colla, Simona, additional

Published
2023
Full Text
View/download PDF

98. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban‐Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C., additional, Kadia, Tapan M., additional, Daver, Naval, additional, Tang, Guilin, additional, Quesada, Andres, additional, Patel, Keyur P., additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P., additional, Kantarjian, Hagop M., additional, Bhalla, Kapil, additional, Garcia‐Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D., additional

Published
2023
Full Text
View/download PDF

99. AML-207 Characteristics and Outcomes of Patients With Acute Myeloid Leukemia and DDX41 Mutation

Author

Bataller, Alex, primary, Loghavi, Sanam, additional, Gerstein, Yoheved, additional, Bazinet, Alexandre, additional, Sasaki, Koji, additional, Chien, Kelly S., additional, Hammond, Danielle, additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautam, additional, Short, Nicholas, additional, Issa, Ghayas C, additional, Kadia, Tapan M, additional, Daver, Naval, additional, Patel, Keyur P, additional, Ravandi, Farhad, additional, Fiskus, Warren, additional, Mill, Cristopher P, additional, Kantarjian, Hagop M, additional, Bhalla, Kapil, additional, Garcia-Manero, Guillermo, additional, Oran, Betul, additional, and DiNardo, Courtney D, additional

Published
2023
Full Text
View/download PDF

100. POSTER: AML-095 Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza)

Author

Konopleva, Marina, primary, DiNardo, Courtney, additional, Sun, Yan, additional, Loghavi, Sanam, additional, Jung, Paul, additional, Potluri, Jalaja, additional, Dail, Monique, additional, Chyla, Brenda, additional, and Pollyea, Daniel, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results